StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.47−0.39 (-1.35%)

Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%

Pfizer free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pfizer's free cash flow for the twelve months ending Jun 28, 2026 was $10.99B, down 11.7% year over year. For fiscal 2025 it was $9.08B, down 7.7% from the year before. Over ten years it grew -3.7% a year on average. The highest annual figure on record is $29.87B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.08B-7.7%
FY2024Dec 31, 2024$9.84B+105.2%
FY2023Dec 31, 2023$4.79B-81.6%
FY2022Dec 31, 2022$26.03B-12.8%
FY2021Dec 31, 2021$29.87B+145.3%
FY2020Dec 31, 2020$12.18B+15.5%
FY2019Dec 31, 2019$10.54B-23.8%
FY2018Dec 31, 2018$13.84B-6.8%
FY2017Dec 31, 2017$14.85B+3.3%
FY2016Dec 31, 2016$14.37B+8.1%
FY2015Dec 31, 2015$13.29B-16.3%
FY2014Dec 31, 2014$15.89B-3.6%
FY2013Dec 31, 2013$16.48B+6.9%
FY2012Dec 31, 2012$15.42B-17.0%
FY2011Dec 31, 2011$18.58B+86.9%
FY2010Dec 31, 2010$9.94B-35.4%
FY2009Dec 31, 2009$15.38B-7.0%
FY2008Dec 31, 2008$16.54B+44.1%
FY2007Dec 31, 2007$11.47B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026$302.00M–
Q1 FY2026Mar 29, 2026$2.18B+23.0%
Q4 FY2025Dec 31, 2025$4.50B-22.4%
Q3 FY2025Sep 28, 2025$4.00B-34.0%
Q2 FY2025Jun 29, 2025-$1.20B–
Q1 FY2025Mar 30, 2025$1.77B+358.8%
Q4 FY2024Dec 31, 2024$5.80B+38.3%
Q3 FY2024Sep 29, 2024$6.06B+129.1%
Q2 FY2024Jun 30, 2024-$2.42B–
Q1 FY2024Mar 31, 2024$386.00M+428.8%
Q4 FY2023Dec 31, 2023$4.20B-44.7%
Q3 FY2023Oct 1, 2023$2.65B-48.5%
Q2 FY2023Jul 2, 2023-$2.12B-128.6%
Q1 FY2023Apr 2, 2023$73.00M-98.8%
Q4 FY2022Dec 31, 2022$7.58B+54.3%
Q3 FY2022Oct 2, 2022$5.13B-49.7%
Q2 FY2022Jul 3, 2022$7.42B-31.1%
Q1 FY2022Apr 3, 2022$5.90B+48.0%
Q4 FY2021Dec 31, 2021$4.91B+2.1%
Q3 FY2021Oct 3, 2021$10.21B+545.0%
Q2 FY2021Jul 4, 2021$10.76B+247.4%
Q1 FY2021Apr 4, 2021$3.98B+48.4%
Q4 FY2020Dec 31, 2020$4.81B+49.1%
Q3 FY2020Sep 27, 2020$1.58B-59.9%
Q2 FY2020Jun 28, 2020$3.10B+45.3%
Q1 FY2020Mar 29, 2020$2.68B+116.8%
Q4 FY2019Dec 31, 2019$3.23B-21.5%
Q3 FY2019Sep 29, 2019$3.95B-16.3%
Q2 FY2019Jun 30, 2019$2.13B-37.7%
Q1 FY2019Mar 31, 2019$1.24B-22.5%
Q4 FY2018Dec 31, 2018$4.11B-35.7%
Q3 FY2018Sep 30, 2018$4.71B+6.2%
Q2 FY2018Jul 1, 2018$3.42B+22.6%
Q1 FY2018Apr 1, 2018$1.60B+30.3%
Q4 FY2017Dec 31, 2017$6.39B+19.4%
Q3 FY2017Oct 1, 2017$4.44B+3.1%
Q2 FY2017Jul 2, 2017$2.79B–
Q1 FY2017Apr 2, 2017$1.23B–
Q4 FY2016Dec 31, 2016$5.35B–
Q3 FY2016Oct 2, 2016$4.31B–

More Pfizer figures

See a number that looks wrong?